Evidence map›Paper›PMID 42515599›Full record

ArticleViruses2026

Identification of Murine Rotavirus Virulence Determinants Using Bidirectional Selective Passaging and a Reverse Genetics System.

Saori Fukuda, Masanori Kugita, Yuki Akari, Johannes M Dijkstra, Yoshiki Kawamura, Shizuko Nagao, Tetsushi Yoshikawa, Takayuki Murata, Satoshi Komoto

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saori FukudaDepartment of Virology, Fujita Health University School of Medicine, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0003-0841-880X
Masanori KugitaAdvanced Medical Research Center for Animal Models of Human Disease, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Yuki AkariDivision of One Health, Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Yufu 879-5593, Oita, Japan.
Johannes M DijkstraOffice of Research Administration, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Yoshiki KawamuraDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0003-3942-7098
Shizuko NagaoAdvanced Medical Research Center for Animal Models of Human Disease, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0003-2014-9411
Tetsushi YoshikawaCenter for Infectious Disease Research, Research Promotion Headquarters, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0002-2847-7682
Takayuki MurataDepartment of Virology, Fujita Health University School of Medicine, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0001-7228-0839
Satoshi KomotoDivision of One Health, Research Center for GLOBAL and LOCAL Infectious Diseases (RCGLID), Oita University, Yufu 879-5593, Oita, Japan.ORCID 0000-0003-2810-8163

Funding

GlaxoSmithKline (Japan) 2021Japan Agency for Medical Research and Development 22fk0108121h0603Japan Agency for Medical Research and Development 23fk0108669h0401Japan Agency for Medical Research and Development 24fk0108669h0402Japan Society for the Promotion of Science 21K07057Japan Society for the Promotion of Science 21K08498Japan Society for the Promotion of Science 24K10235Japan Society for the Promotion of Science 24K11806Kaketsuken (Japan) KaketuskenMochida Memorial Foundation For Medical And Pharmaceutical Research Mochida Memorial Foundation for Medical and Pharmaceutical ResearchTakeda Science Foundation Takeda Science Foundation
6 · The paper itself

Abstract

Live-attenuated rotavirus (RV) vaccines are the most effective interventions for preventing RV gastroenteritis (RVGE) in young children. However, the molecular basis of attenuation remains not well understood. Here, we describe a compact but comprehensive strategy to identify RV virulence determinants by combining low-passage bidirectional selection, sequence analysis, and segment-level phenotype testing via a reverse genetics infectious system. Using the virulent murine RV strain EW, virulence was quantified by diarrhea severity/duration and body-weight gain. Serial passaging in cell culture selected an attenuated population, which regained virulence after passaging in suckling mice. Sequence comparison of the virulent and attenuated EW populations revealed only seven amino acid differences. We summarized literature describing attenuation/virulence-associated mutations in various RV group A (RVA) strains and found previous findings identical or similar to four of the seven mutations: NSP4-T45M, VP4-S470L, VP4-T612A, and VP7-T75P. Virulent- and attenuated-type EW variants of VP2, VP4, VP7, and NSP4 were introduced individually, or as NSP4/VP7 or VP4/VP7 pairs, into a simian SA11-L2 backbone using an 11-plasmid reverse genetics system. Phenotyping of rescued viruses consistently linked cell-culture-adapted VP4 to enhanced replication in vitro and reduced virulence in suckling mice. In vivo passaging strongly favored VP4 residue S470 over cell-culture-selected L470. More generally, our findings (i) underscore VP4 and VP7 as key determinants of EW virulence, (ii) provide a practical framework for identifying driver mutations underlying RVA attenuation, and (iii) highlight attenuation-associated substitutions shared across diverse RVAs.

Indexed as

Reverse GeneticsRotavirusRotavirus InfectionsVirulence FactorsAnimalsMiceMutationRotavirus VaccinesSerial PassageVaccines, AttenuatedVirulenceRotavirus VaccinesVaccines, AttenuatedVirulence Factorsattenuationpathogenicityreverse geneticsrotavirusvaccine

Identifiers

PMID42515599
PMCPMC13431595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.